SCHEMBL6483504

SCHEMBL6483504

COc1cccc(C(=O)CC(=O)C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.56
CES1 P23141 1/20 0.56
NPC1 O15118 5/20 0.53
RAB9A P51151 5/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
POLB P06746 1/20 0.53
BLM P54132 1/20 0.53
PARP1 P09874 1/20 0.53
KMT2A Q03164 4/20 0.52
TSHR P16473 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
MEN1 O00255 2/20 0.51
CHRM2 P08172 1/20 0.51
CHRM1 P11229 1/20 0.51
CHRM3 P20309 1/20 0.51
HSD11B1 P28845 1/20 0.51
PLOD2 O00469 1/20 0.50
PLOD3 O60568 1/20 0.50
PLOD1 Q02809 1/20 0.50
GAA P10253 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30758862 0.85 CES2 (0.69) CES2CES1NPC1RAB9ASMN1; SMN2
SCHEMBL11248287 0.85 CES2 (0.69) CES2CES1NPC1RAB9ASMN1; SMN2
SCHEMBL6485630 0.82 GAA (0.61) NPC1RAB9ASMN1; SMN2KMT2ATSHR
SCHEMBL2278242 0.81 CES2 (0.62) CES2CES1NPC1RAB9ASMN1; SMN2
SCHEMBL30626936 0.81 CES2 (0.62) CES2CES1NPC1RAB9ASMN1; SMN2
SCHEMBL8889322 0.81 KMT2A (0.68) CES2CES1NPC1RAB9ASMN1; SMN2
SCHEMBL709889 0.81 PLOD2 (0.64) NPC1KMT2APLOD2PLOD3PLOD1
SCHEMBL1421198 0.81 CES2 (0.62) CES2CES1NPC1RAB9ASMN1; SMN2
SCHEMBL2130116 0.81 CES2 (0.62) CES2CES1NPC1RAB9ASMN1; SMN2
SCHEMBL3846484 0.80 PARP1 (0.67) CES2CES1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-6919470-B2 Aryl and heteroaryl sulfonates BAYER AKTIENGESELLSCHAFT (DE) 2005-07-19 US disclosed
US-20030232802-A1 Aryl and heteroaryl sulfonates HEIL MARKUS (DE) 2003-12-18 US disclosed
EP-1278722-A1 ARYL AND HETEROARYL SULFONATES Bayer Aktiengesellschaft (DE) 2003-01-29 EP disclosed
WO-2001074763-A1 ARYL AND HETEROARYL SULFONATES BAYER AKTIENGESELLSCHAFT (DE) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232802-A1 Aryl and heteroaryl sulfonates ARSA, SNCA, ATXN2 CES2 267/4885CES1 180/4885NPC1 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.